Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Evaxion A/S changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 9 | 6 | −3 |
| Shares | 447.2K | 381.0K | −66.1K (−14.8%) |
| Value | $314.2K | $1.22M | +$905.1K (+288.1%) |
New holders (2)
Institutions that held Evaxion A/S at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 367,000 | $1.17M | 0.03% |
| Tower Research Capital LLC (TRC) | 30 | $96 | 0.00% |
Sold out (5)
Institutions that held Evaxion A/S at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| LM Advisors LLC | 337,336 | $231.3K |
| Renaissance Technologies LLC | 14,000 | $10.0K |
| Moloney Securities Asset Management, LLC | 10,000 | $6.86K |
| Group One Trading, L.P. | 386 | $265 |
| UBS Group AG | 277 | $190 |